Eton Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ETON$67.54+5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| For the nine months ended | ||
|---|---|---|
| September 30, 2026 | September 30, 2025 | |
| Operating Activities | ||
| Net income (loss) | $48,381 | $(6,084) |
| Adjustments to reconcile net income (loss) to net cash from operating activities: | ||
| Stock-based compensation | 6,295 | 4,388 |
| Depreciation and amortization | 3,961 | 3,027 |
| Inventory step-up | 1,470 | 3,673 |
| Excess and obsolete inventory reserve | 620 | 337 |
| Debt discount amortization and non-cash interest expenses | 488 | 521 |
| Non-cash lease expense | 96 | 35 |
| Acquired in-process research and development | 3,000 | — |
| Reversal of deferred tax asset valuation allowance | (12,892) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (14,734) | (7,721) |
| Inventories | 3,377 | (5,632) |
| Prepaid expenses and other assets | 3,817 | 550 |
| Accounts payable | 5,523 | 10,092 |
| Accrued Medicaid rebates | 336 | 11,165 |
| Accrued liabilities | 5,460 | 585 |
| Other non-current assets and liabilities | (5,297) | 7,139 |
| Net cash from operating activities | $49,901 | $22,075 |
| Investing Activities | ||
| Purchases of product license rights | $(18,225) | $— |
| Purchases of property and equipment | (83) | (284) |
| Net cash used in investing activities | $(18,308) | $(284) |
| Financing Activities | ||
| Proceeds from stock option exercises | $5,823 | $394 |
| Proceeds from ESPP shares issued | 270 | — |
| Repayment of long-term debt | (8,000) | — |
| Net cash (used in) from financing activities | $(1,907) | $394 |
| Change in cash and cash equivalents | $29,686 | $22,185 |
| Cash and cash equivalents at beginning of period | 25,942 | 14,936 |
| Cash and cash equivalents at end of period | $55,628 | $37,121 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | $2,401 | $2,395 |
| Cash paid for income taxes, net | $106 | $117 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.